Study to Assess Management Strategies for the Use of Esomeprazole (Nexium) in Helicobacter Pylori Infected Patients

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE4

Study Classification

INTERVENTIONAL

Study Start Date

2003-11-30

Study Completion Date

2007-10-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The primary objective of this study is to investigate whether eradication treatment of Helicobacter pylori followed by therapy with esomeprazole for a total of 8 weeks extends the time to relapse in patients with gastroesophageal reflux disease (GERD).

A relapse is defined by two consecutive symptom scores of the Eraflux questionnaire within 14 days that are equal or above the critical value of 25.

The secondary objectives are

1. To compare the time to relapse in the two H. pylori positive study groups with the H. pylori negative control group
2. To compare the pattern of inflammation and atrophy in the two H. pylori positive treatment groups with the naturally H. pylori negative control group at relapse.
3. All the above objectives analyzed for the efficacy subset that is the per-protocol patients broken down by effective H. pylori-eradication.

Secondary endpoints will be analyzed by the following parameters and their interactions:

1. Treatment : Eradicated, Non-eradicated, Hp-negative control
2. Esophagitis at study start: grades 0, A/B and C/D
3. Gender
4. Alcohol intake
5. NSAID/ASA intake (for histological results)

* Trial with medicinal product

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Gastroesophageal Reflux Disease (GERD)

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

H. pylori

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Esomeprazole

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

For inclusion in the study the subject must fulfill all of the following criteria:

1. Patients aged between 18 and 70 years.
2. Chronic symptoms (\>8 weeks) suggestive for GERD, as defined in Table 2 with or without reflux esophagitis grade A-D (Los Angeles classification)
3. Indication for endoscopy due to GERD symptoms is given
4. Written informed consent

Table 2: Lead GERD criteria

For inclusion in the study, all of the following lead GERD criteria should hold:

* At least one of the symptoms heartburn or regurgitation.
* At least 8 weeks ongoing symptoms.
* At least 3 times a week.
* At least moderate intensity, corresponding to light impairment in daily life and occasional need for drugs.

Exclusion Criteria

Any of the following is regarded as a criterion for exclusion from the study:

1. Severe organic esophageal disease other than reflux esophagitis (e.g. carcinoma, esophageal stenosis).
2. Gastric or duodenal ulcers
3. Patients with visible Barrett's mucosa; no histological confirmation is required for exclusion
4. History of previous esophageal or gastric surgery
5. Alcohol or drug abuse
6. Severe organic or psychiatric disease
7. Pregnancy or lactation
8. Women with child-bearing potential if no medically accepted contraceptive measures are used
9. Contra-indication to amoxicillin, clarithromycin or esomeprazole (Nexium)
10. Need for concomitant medication which could interfere with the investigational products (substrates of CYP3A4)
11. Suspected or confirmed poor compliance
12. Participation in a clinical study within 8 weeks prior to enrollment.

Minimum Eligible Age

18 Years

Maximum Eligible Age

70 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Werner Schwizer, MD

Role: PRINCIPAL_INVESTIGATOR

UniversitaetsSpital Zuerich

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

University Hospital Zurich

Zurich, , Switzerland

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Switzerland

References

Explore related publications, articles, or registry entries linked to this study.

Schwizer W, Menne D, Schutze K, Vieth M, Goergens R, Malfertheiner P, Leodolter A, Fried M, Fox MR. The effect of Helicobacter pylori infection and eradication in patients with gastro-oesophageal reflux disease: A parallel-group, double-blind, placebo-controlled multicentre study. United European Gastroenterol J. 2013 Aug;1(4):226-35. doi: 10.1177/2050640613484020.

Reference Type DERIVED

PMID: 24917966 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

ACH-QBE-0201

Identifier Type: -

Identifier Source: org_study_id